NCT00581035

Study Evaluating the Safety and Ability to Produce Immune Response of Prevenar and Meningitec Given at the Same Time

A Randomised Open Label Phase 4 Study to Evaluate the Safety and Immunogenicity of Concomitant Prevenar and Meningitec Compared to Prevenar Alone and Meningitec Alone When Used as Part of the Routine Vaccination Series in Healthy Infants

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 712 (actual)
• Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer · Industry
• Sex: All
• Age: 42 Days – 63 Days
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the safety and immunogenicity of concomitant Prevenar and Meningitec compared to Prevenar alone and Meningitec alone when used as part of the routine vaccination series in healthy infants

Conditions

• Healthy

Interventions

Type	Name	Description
BIOLOGICAL	Prevenar and Meningitec	1 dose of Prevenar at 2,3.5,6 and 12 months and 1 dose of Meningitec at 2,6 and 12 months
BIOLOGICAL	Prevenar	1 dose at 2,3.5,6 and 12 months
BIOLOGICAL	Meningitec	1 dose at 2,6 and 12 months

Timeline

• Start date: 2006-01-01
• Completion: 2007-05-01
• First posted: 2007-12-27
• Last updated: 2007-12-27